Dangerous organophosphorus (OP) compounds have been used as insecticides in agriculture and in chemical warfare. Because exposure to OP could create a danger for humans in the future, butyrylcholinesterase (BChE) has been developed for prophylaxis to these chemicals. Because it is impractical to obtain sufficient quantities of plasma BChE to treat humans exposed to OP agents, the production of recombinant BChE (rBChE) in milk of transgenic animals was investigated. Transgenic mice and goats were generated with human BChE cDNA under control of the goat ␤-casein promoter. Milk from transgenic animals contained 0.1-5 g/liter of active rBChE. The plasma half-life of PEGylated, goat-derived, purified rBChE in guinea pigs was 7-fold longer than non-PEGylated dimers. The rBChE from transgenic mice was inhibited by nerve agents at a 1:1 molar ratio. Transgenic goats produced active rBChE in milk sufficient for prophylaxis of humans at risk for exposure to OP agents.
H
uman plasma butyrylcholinesterase (huBChE) (EC 3.1.1.8) is a globular, tetrameric serine esterase with a molecular mass of Ϸ340 kDa that is stable in plasma with a half-life of Ϸ12 days (1, 2) . Although the physiological function of huBChE is unclear, the enzyme prevents intoxication of animals exposed to organophosphorus (OP) compounds (3, 4) . The huBChE enzyme also hydrolyzes many ester-containing drugs, such as cocaine and succinylcholine (5) . The toxicity of OP agents is due to irreversible inhibition of acetylcholinesterase and the subsequent continuous stimulation of neurons by acetylcholine (6) . Administration of exogenous huBChE, which irreversibly binds OP agents to prevent inactivation of acetylcholinesterase and continuous cholinergic stimulation, is a potential strategy for preventing toxicity from OP agents (4) . Although huBChE has been obtained from human plasma by a large scale purification technique, this procedure is severely limited by the volume of human plasma needed (7) . It is unlikely that a sufficient amount of enzyme could be purified commercially by this technique. Because of the 1:1 stoichiometry required for protection against exposure to OP agents (8) , large quantities of huBChE are needed for effective prophylaxis and treatment of exposure. Compared with other potential enzymatic bioscavengers of OP agents, huBChE has a broad spectrum of activity, a relatively long half-life, and limited, if any, physiological side effects (9) . Producing recombinant BChE (rBChE) is an alternative to purification of the enzyme from human plasma. Recombinant huBChE has been expressed in Escherichia coli (10) , albeit in a nonfunctional form; mammalian 293T (11) ; and CHO (12) cells. However, these expression systems cannot economically produce sufficient quantities of rBChE with a residence time similar to native huBChE that would allow development of the enzyme as an agent for prophylaxis against OP poisoning.
The production of recombinant proteins by the mammary gland of transgenic animals is well established (13, 14) . A variety of recombinant human proteins, including immunoglobins, growth hormone, and clotting factors have been expressed by the mammary gland and secreted in the milk of transgenic animals (13) . This article describes the production of functional rBChE in the milk of transgenic mice and goats and the characterization of the recombinant protein. These studies illustrate the feasibility of producing large quantities of rBChE in transgenic animals for prophylaxis or treatment of humans exposed to OP agents.
Results

Generation of rBChE Transgenic Animals.
A DNA expression vector, bCN-BChE, was developed to contain a 2.4-kb dimerized chicken ␤-globin gene insulator; a 6.7-kb goat ␤-casein gene promoter fragment, including the signal sequence in exon 2; a 1.7-kb human BChE cDNA fragment amplified from a huBChE cDNA clone [American Type Culture Collection (ATCC), Manassas, VA; catalog no. 65726]; and a 6.1-kb fragment consisting of the ␤-casein coding and 3Ј noncoding regions (Fig. 1A) . The plasmid backbone of bCN-BChE was removed by NotI digestion. The 16.9-kb rBChE transgene fragment was then gel-purified and microinjected into the pronuclei of in vitro-produced zygotes to generate transgenic mice and goats. Four F 0 founder mice, two males and two females, and six F 0 founder goats, one male and five females, were generated. Southern blot and FISH analyses ( Fig. 1 B-D and Table 1 ) revealed that the transgenic animals carried a variety of the rBChE transgene copies inserted randomly in their genomes. The transgene integrated in tandem head to tail or head to head arrays, as confirmed by Southern blot (data not shown). Two transgenic founder mice, 43-3M and 61-2F, and four transgenic founder goats, 1871F, 1876M, 1880F, and 1900F, bred with wild-type animals of the same strain transmitted the gene construct to their offspring. In addition, cloned copies of a selected female founder goat 1871F were generated by the somatic cell nuclear transfer technique (15) . However, compared with the founder goat 1871F, reduced transgene copy numbers (10) (11) (12) and one integration site were detected from some of the cloned copies, as indicated by Southern blot and FISH analyses ( Fig. 1D and Table 1) , suggesting a mosaic expression pattern of the transgene in different cell populations in the founder goat. F 1 goats of the cloned copies of the founder goat were produced by a laparoscopic ovum pick-up-in-vitro fertilization technique (16) . Initial herd expansion was performed in nontransgenic goats of New Zealand origin by artificial insemination from a master semen bank established from one of the male transgenic F 1 goats, 2219M, after it was established that this goat, along with other F 1 goats from the transgenic goat founder line, 1871F, also had 10-12 transgene copies integrated into a single chromosomal site in the genome (Table 1) . Transgenic animals reported in this study were viable and healthy. Herd expansion of the rBChE transgenic goats is ongoing and is anticipated to produce all of the rBChE required for the preclinical and clinical studies evaluating rBChE for use in prophylaxis or treatment of OP intoxication. A herd of nontransgenic goats of New Zealand origin maintained within a biosecurity facility were the recipients of the artificial insemination program for generation of transgenic offspring that will constitute the commercial production herd. A total of 313 births have occurred with 615 live kids. Of 284 female kids, 121 were transgenic.
Southern blot and FISH analyses revealed that most of the transgenic goats have 10-12 transgene copies and one integration site in the genomes, similar to the herd expansion originator goat 2219M.
Expression of rBChE in the Milk of Transgenic Animals. Milk samples from transgenic animals, collected after initiation of induced or natural lactation, were analyzed for the presence of the rBChE, using nondenaturing polyacrylamide gels stained for cholinesterase activity (17) . The rBChE produced in the milk of the transgenic animals migrated as a mixture of dimer, tetramer and monomer, with dimer as the predominant form ( Fig. 2A , lanes 2-4 for mouse milk, and Fig. 2B , lanes 3-5 for goat milk). Variation in the amount of the tetramer produced by the transgenic animals was also observed (Fig. 2 A, lanes 2-4 and Fig.  2B lanes 3-5) . The endogenous mouse BChE, detected from the milk of a low rBChE expression line, 44-2F (Fig. 2 A, lane 4) , and a negative control mouse (Fig. 2 A, lane 5) , migrated differently from the rBChE. Western blot analysis under denaturing and reducing conditions with a polyclonal anti-huBChE antibody confirmed the expression of the rBChE in the milk of the transgenic animals migrating at the expected size of the protein (Ϸ90 kDa) ( Fig. 2 C and D) . The rBChE expressed in the milk of transgenic animals was a doublet of Ϸ90 kDa, which may represent different glycosylation states of the overexpressed protein. Other bands that could be identified on the Western blot with the same antibody in both the positive control (Fig. 2D , lane 1) and the milk samples (Fig. 2D, lanes 3-5) were a few minor bands with molecular masses Ͼ90 kDa, probably because of nonreduced forms of BChE. The identification of the oligomeric form of rBChE was based on migration relative to plasma huBChE. Plasma-derived huBChE (kindly provided by O. Lockridge, University of Nebraska, Omaha, NE) contained two bands, with the tetramer being the major species ( Fig. 2 A and 
B, lane 1).
To gain further insight into the distribution of the oligomeric forms of the rBChE during lactation, raw milk samples from 12 F 2 transgenic goats were centrifuged and loaded into a size exclusion chromatography (SEC)-HPLC system. Collected fractions then were analyzed by the Ellman assay (18), and the oligomeric profile of the raw milk material was determined (Fig. 2E) , confirming that the dimer is the major oligomeric form in the milk of the transgenic goats throughout the entire lactation period. SEC-HPLC combined with the Ellman assay, therefore, was a reliable and practical method to analyze the distribution of the oligomeric forms from the raw milk of transgenic goats.
Through herd expansion, kilogram quantities of rBChE have been produced in the milk of the transgenic female goats with Ͼ50 first lactations now completed. The rBChE concentration was consistently in the range of 1-5 g/liter throughout the entire lactation period, as assessed by the Ellman assay (Table 1 ). The rBChE expression data clearly demonstrate that rBChE is produced and secreted by the mammary gland of the transgenic animals. The purity of rBChE purified from the milk of transgenic goats was consistently Ͼ95%, as assessed by the silver-stained SDS/PAGE (Fig. 2F) . The purified rBChE showed a similar 90-kDa doublet as described above. There were only minor differences in migration of huBChE purified from plasma and rBChE purified from the milk of transgenic goats, presumably because of differences in glycosylation between proteins from the two sources.
Pharmacokinetics of rBChE in Guinea Pigs. Once purified, the rBChE enzyme secreted in goat's milk had a short plasma half-life after either i.v. (Fig. 3A) or intramuscular injection (Fig. 3B) into guinea pigs. There was a significant improvement in the plasma half-life of the enzyme after modification with PEG ( Fig. 3 A and B) . PEGylation of the purified rBChE was performed with PEG 20,000, using lysine linkage chemistry. SDS/PAGE and SEC-HPLC/light scattering revealed that one to three PEGs were attached to each rBChE molecule (data not shown). Data from compartmental analysis provided estimates of pharmacokinetic parameters following i.v. and intramuscular administration of PEGylated and dimeric rBChE to male guinea pigs. The bioavailability of PEGylated rBChE was Ϸ46% with a plasma half-life of Ϸ44 h. By comparison, the bioavailability of unmodified dimer rBChE was Ϸ7.3% with a plasma half-life of Ϸ6.5 h ( Table 2) .
Activity of Expressed rBChE. In in vitro inhibition assays with the OP nerve agents soman (GD), sarin (GB), tabun (GA), or VX rBChE from transgenic mouse milk was inhibited at a molar ratio of Ϸ1:1 (Fig. 4) . Similar inhibitory profiles were seen when purified rBChE from milk of transgenic goats was mixed with soman, sarin, tabun, or VX, using varying molar ratios of enzyme to nerve agent (8:1, 4:1, 1:1, and 1:4, respectively) (3).
The glycan components of the rBChE purified from goat's milk collected during early, middle, and later stages of a natural lactation were analyzed (Table 3) . Compared with native BChE purified from human serum, the rBChE is underglycosylated, with more fucose and GalNac and less mannose, galactose, GlcNac, and sialic acid.
Discussion
Human BChE has a broad spectrum of efficacy against OP compounds used as nerve agents and is a promising bioscavenger for the treatment of humans exposed to these agents (4) . Because the quantities of this enzyme that can be extracted and purified from human plasma are limited by the availability of out-dated human blood, recombinant DNA technology can play a major role in producing the quantities of enzyme needed for large scale use of this enzyme as an OP bioscavenger. To examine the feasibility of producing large quantities of rBChE in the milk of transgenic animals, rBChE was expressed first in transgenic mice as a proof-of-concept step, then in transgenic goats. By placing the rBChE gene under the control of the goat ␤-casein promoter, the rBChE protein can be produced in the milk of goats at concentrations of up to 5 g/liter. The ability to produce large quantities of rBChE in the milk of transgenic animals enables production of large quantities of active enzyme for prophylaxis or treatment of humans exposed to OP agents.
The tetrameric form of huBChE is retained in the circulation much longer than the rBChE produced in cell culture systems (19) . The half life of the native enzyme in the circulation is influenced by 
The concentrations for expression of rBChE, estimated by densitometry where 720 units ϭ 1 mg of purified BChE were estimated from at least two independent assays. NA, not applicable; ND, not determined; BG, background; M, male; F, female; -, not available. Transgene copy numbers and integration sites of transgenic animals were determined by Southern blot and FISH analyses (see SI Materials and Methods). rBChE concentration (g/liter) in the milk of transgenic goats was determined by the Ellman assay.
the oligomerization of the enzyme and the heterogeneity in charge and size because of the surface glycans (20) . Staining for rBChE on nondenaturing activity gels and analyses of the raw milk samples by SEC-HPLC indicate that the expressed enzyme is mainly in the dimeric form. By comparison, the BChE isolated from human plasma was predominately a tetramer. An in vitro expression cassette with the same rBChE cDNA used to generate the transgenic mice and goats was expressed in MAC-T, a bovine mammary gland epithelial cell line, with production of a predominately tetrameric form of the enzyme (A.L. and Y.-J.H., unpublished data). ColQ PRAD peptide, a proline-rich attachment domain encoded by the ColQ gene, is necessary for efficient assembly of the tetrameric forms of BChE and acetylcholinesterase in vitro and in vivo (11, 19, 21) . It is possible that the higher level of expression of rBChE by mouse and goat mammary glands might have exceeded the capacity of the intracellular protein assembly machinery to efficiently assemble tetramers, such that they are a minor component of the total rBChE produced. There may not be enough ColQ PRAD peptide available in this expression system, thereby altering the oligomeric distribution of the rBChE secreted in the milk of transgenic animals.
Glycosylation is one of the most important posttranslational modifications of proteins (22) . Glycans on tetrameric forms of human, equine, and fetal bovine plasma cholinesterases in serum contain predominantly complex bi-antennary glycan structures, which may increase the stability of these enzymes in the circulation (20) . Mammary gland cells have the capacity to secrete proteins that are N-or O-glycosylated. There have been numerous recombinant proteins expressed and secreted in the milk of transgenic animals. Some of them, for example, ␣1-antitrypsin and superoxide dismutase, are glycosylated like their native counterparts (22) . Others, such as human tissue plasminogen activator and human antithrombin III, are underglycosylated or not glycosylated in an appropriate manner (23) . It is clear that the dimeric rBChE purified from goat's milk was underglycosylated, especially with sialic acid, as compared with BChE from human plasma. These differences in glycosylation of recombinant proteins may have more impact on in vivo stability than on biological activity (22) .
PEGylation often improves the pharmacokinetic and toxicity profiles of recombinant proteins (24) . Attachment of hydrophilic PEG molecules to a peptide or protein improves water solubility and forms a barrier to prevent enzyme degradation, renal clearance, interaction with cell surface proteins, or development of neutralizing antibodies (24) . In this study, the significant increase in the plasma half-life of the PEGylated rBChE purified from the milk of transgenic goats and administered to guinea pigs compared with the native rBChE dimer suggests that, despite poor glycosylation of the recombinant protein, PEGylation is an effective strategy to improve the pharmacokinetic profile of this enzyme. To successfully use the milk expression system in transgenic animals for manufacturing large quantities of rBChE, it is essential that the enzyme be functionally similar to huBChE. The administration of purified, PEGylated, rBChE from goat milk, in the absence of any other pretreatments or therapy, was found to protect guinea pigs against exposure to multiple lethal doses of the nerve agents VX or soman, with 100% survival and no signs of toxicity [L. A. Lumley, C. L. Robison, B. Somsamayuong, and D.M.C., unpublished data; please also see a review by Lenz et al. (4) ]. The in vivo efficacy data in guinea pigs from the goat milk-derived and PEGylated rBChE as well as in vitro nerve agent binding and inhibition experiments with rBChE from the milk of transgenic mice or purified from the milk of transgenic goats indicated that the expressed enzyme was similar to huBChE in plasma with regard to activity against a variety of nerve agents, suggesting that the rBChE produced in the milk of transgenic goats will likely be a useful bioscavenger of OP nerve agents.
Transgenic animal technology has been used extensively in biomedical and agricultural research (25) . The use of transgenic farm animals to produce pharmaceutically important recombinant proteins, such as antibodies, anti-clotting factors, and growth factors, in the mammary gland is well documented (26) . Compared with other farm animal species, the goat is frequently used because of its relatively low cost of maintenance and faster breeding (27) . The present study demonstrates the feasibility of large-scale production of rBChE in transgenic goats with kilogram quantities of functional recombinant huBChE produced in the milk of transgenic goats. The use of transgenic goats as bioreactors for the production of functional rBChE will provide a reliable source of this enzyme for prophylaxis or treatment of humans exposed to OP compounds used as agricultural or chemical warfare agents.
Methods
Production of Founder and Subsequent Generation of Transgenic
Animals. The rBChE transgene DNA expression cassette was constructed as described in supporting information (SI) Materials and Methods. Transgenic mice were produced and maintained at McIntyre Transgenic Core Facility of McGill University (Montreal, QC, Canada). Animal studies were carried out in accordance with guidelines on the care and use of experimental animals from the Canadian Council of Animal Care. Transgenic mice were generated in a friend virus B-type (FVB) background strain (Charles River Laboratories, Wilmington, MA) as described in ref. 28 . The bCN-BChE expression vector containing the transgene was microinjected into fertilized eggs, and 22 pups were born. At 2-3 weeks of age, tail biopsies were taken under anesthesia, and DNA was prepared according to standard procedures (29) . Transgenic founder mice were bred with wild-type mice of the same strain for the production of F 1 , F 2 , and F 3 generations.
The production and maintenance of transgenic goats were conducted at the PharmAthene Canada Caprine Production Farm. Animal studies were carried out according to protocols approved by the Animal Care Committee of PharmAthene Canada. The production of the founder goats and subsequent generation of rBChE transgenic goats was performed as described in ref. 30 . Briefly, 3 g/ml of the transgene DNA fragment were microinjected into in vitro produced goat zygotes. After a brief in vitro culture, the zygotes were transferred to recipient goats and pregnancies confirmed by transrectal ultrasonography. Newborn kids were separated from recipient goats at birth to prevent disease transmission. Transgenic founder goats were bred with wild-type goats of the same strain for the production of subsequent generations. Cloned copies of a selected female founder goat, 1871F, were generated by somatic cell nuclear transfer (15) . F 1 goats of the cloned copies of the founder goat were obtained by laparoscopic ovum pick-up-invitro fertilization as described in ref. 31 . Herd expansion was performed in nontransgenic New Zealand herd goats by artificial insemination from a master semen bank established from one of the male transgenic F 1 goats, 2219M and some of its male offspring. Transgenic female goats were hormonally induced into lactation (32) at 2 months of age to measure expression of rBChE in the milk before natural lactation took place at 12 months age. rBChE transgenic animals were identified and characterized by PCR, Southern blot and FISH analysis. The methods are described in SI Materials and Methods.
SEC-HPLC of rBChE in the Milk of Transgenic Goats. Raw milk samples collected from 12 F2 transgenic goats during natural lactation were centrifuged twice for 90 seconds each at room temperature at 9,300 ϫ g, and the clear supernatants were diluted 40-fold with a HPLC mobile phase containing 20 mM NaP, 200 mM NaCl, and 0.04% NaN 3 . The samples were then filtered through a syringe-driven 0.22-m filter. A 10-l aliquot of each sample was injected and analyzed on a SEC-HPLC system (Waters Alliance 2695 separations module; Waters, Milford, MA) with UV detection at 280 nm. The SEC column used was a Shodex (Kawasaki, Japan) KW-803 (8 mm ϫ 300 mm with an exclusion limit of 1.7 ϫ 10 5 and minimum of 21,000 theoretical plates). The Shodex protein KW-G guard column (6 mm ϫ 50 mm) was used with the column. Separation of tetramer, dimer, and monomer peaks of the rBChE in the milk was obtained. Collected fractions were analyzed by the Ellman assay. Data were plotted as rBChE specific activity versus SEC-HPLC collection intervals. By using area counts, the percentages of tetramer, dimer, and monomer were determined.
PEGylation of Purified rBChE. rBChE activity assay and rBChE purification were performed as described in SI Materials and Methods. Purified rBChE (0.5 mg/ml) was mixed quickly with PEG 20,000 at a ratio of 1:80 in 50 mM sodium phosphate, pH 8.0 and incubated at 24°C for 2 h. The PEGylated proteins were then purified by affinity chromatography with a procainamide column as described above.
Pharmacokinetic Studies of rBChE. Pharmacokinetic studies in animals were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the U.S. National Institutes of Health and were conducted by MDS Pharma Services (Laval, Quebec, Canada). Male Hartley guinea pigs (Charles River) were divided into three groups. Animals in Groups 1 and 2 received the test article by i.v. and intramuscular injection, respectively, whereas those in Group 3 received a vehicle control via intramuscular injection. The guinea pigs were injected with 72.3 mg/kg purified PEGylated rBChE (n ϭ 14, 12, and 4 in Groups 1, 2, and 3, respectively) or 79.4 mg/kg purified rBChE dimers (n ϭ 9, 12, and 12 in Groups 1, 2, and 3, respectively). Timed blood samples were collected from the animals for 192 h after dosing, and BChE activity was tested by the Ellman assay. The pharmacokinetic data were analyzed by a two-compartment model with NONMEM software, Version 5 (GloboMax, Ellicott City, MD) with data from Group 3 fit into the model as random variability.
In Vitro Inhibition of rBChE by OP Agents. rBChE contained in the milk of transgenic mice was combined with different concentrations of the OP agents soman (GD), sarin (GB), tabun (GA), or VX and incubated at 25°C for 10 min, using the proper safety precautions. The BChE activity for each incubation was measured by the Ellman assay, and the results were expressed as a percentage of residual activity. Data were plotted and analyzed by using Microsoft Excel (Microsoft, Redmond, WA).
Carbohydrate Analysis of rBChE. Monosaccharide analysis of purified rBChE in dimer form from the milk of 2220F, a F 1 transgenic goat, was performed by GlycoSolutions (Worcester, MA).
